Literature DB >> 2555389

Establishment of titration system for human herpesvirus 6 and evaluation of neutralizing antibody response to the virus.

H Asada1, S Yalcin, K Balachandra, K Higashi, K Yamanishi.   

Abstract

The susceptibilities of seven T-cell lines to human herpesvirus 6 (HHV-6) infection were examined. MT-4 cells were the most susceptible of these lines to infection with this virus. Therefore, chemically adhered MT-4 cell monolayers were used for infectious HHV-6 assay by indirect immunofluorescent-antibody (IFA) staining. When cell monolayers were fixed 30 to 45 h postinfection, the foci stained with IFA were easy to count and a linear relationship was observed between the number of foci and the virus concentration. MT-4 cell monolayers were also used for a focus reduction neutralizing-antibody test. In this test, sera from patients in the convalescent stage of exanthem subitum all showed significant neutralizing activity (1:80 to 1:320), whereas sera from patients in the acute stage of disease showed no detectable neutralizing activity. The titers of neutralizing antibody correlated well with the levels of anti-HHV-6 antibodies detected by IFA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555389      PMCID: PMC266994          DOI: 10.1128/jcm.27.10.2204-2207.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

2.  HBLV (or HHV-6) in human cell lines.

Authors:  D V Ablashi; S Z Salahuddin; S F Josephs; F Imam; P Lusso; R C Gallo; C Hung; J Lemp; P D Markham
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

3.  DNA homology between a novel human herpesvirus (HHV-6) and human cytomegalovirus.

Authors:  S Efstathiou; U A Gompels; M A Craxton; R W Honess; K Ward
Journal:  Lancet       Date:  1988 Jan 2-9       Impact factor: 79.321

4.  Concomitant infection by human herpesvirus 6, HTLV-I, and HIV-2.

Authors:  H Agut; D Guetard; H Collandre; C Dauguet; L Montagnier; J M Miclea; H Baurmann; A Gessain
Journal:  Lancet       Date:  1988-03-26       Impact factor: 79.321

5.  Diverse tropism of HBLV (human herpesvirus 6)

Authors:  P Lusso; S Z Salahuddin; D V Ablashi; R C Gallo; F Di Marzo Veronese; P D Markham
Journal:  Lancet       Date:  1987-09-26       Impact factor: 79.321

6.  Isolation of human lymphotropic herpesviruses from Uganda.

Authors:  R G Downing; N Sewankambo; D Serwadda; R Honess; D Crawford; R Jarrett; B E Griffin
Journal:  Lancet       Date:  1987-08-15       Impact factor: 79.321

7.  Membrane and other phenotypes of leukemia cells.

Authors:  J Minowada
Journal:  Prog Clin Biol Res       Date:  1983

8.  Identification of human herpesvirus-6 as a causal agent for exanthem subitum.

Authors:  K Yamanishi; T Okuno; K Shiraki; M Takahashi; T Kondo; Y Asano; T Kurata
Journal:  Lancet       Date:  1988-05-14       Impact factor: 79.321

9.  Plaque formation and isolation of pure lines with poliomyelitis viruses.

Authors:  R DULBECCO; M VOGT
Journal:  J Exp Med       Date:  1954-02       Impact factor: 14.307

10.  In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6).

Authors:  P Lusso; P D Markham; E Tschachler; F di Marzo Veronese; S Z Salahuddin; D V Ablashi; S Pahwa; K Krohn; R C Gallo
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Analysis of a neutralizing antibody for human herpesvirus 6B reveals a role for glycoprotein Q1 in viral entry.

Authors:  Akiko Kawabata; Hiroko Oyaizu; Takahiro Maeki; Huamin Tang; Koichi Yamanishi; Yasuko Mori
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Humanization of Murine Neutralizing Antibodies against Human Herpesvirus 6B.

Authors:  Bochao Wang; Mitsuhiro Nishimura; Yuji Maekawa; Toshiya Kotari; Toshiomi Okuno; Yasuko Mori
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

4.  An Animal Model That Mimics Human Herpesvirus 6B Pathogenesis.

Authors:  Bochao Wang; Yasuyuki Saito; Mitsuhiro Nishimura; Zhenxiao Ren; Lidya Handayani Tjan; Alaa Refaat; Rie Iida-Norita; Ryuko Tsukamoto; Masato Komatsu; Tomoo Itoh; Takashi Matozaki; Yasuko Mori
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

5.  Variation of DNA sequence in immediate-early gene of human herpesvirus 6 and variant identification by PCR.

Authors:  T Yamamoto; T Mukai; K Kondo; K Yamanishi
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

6.  Frequent detection of the human herpesvirus 6-specific genomes in the livers of children with various liver diseases.

Authors:  Y Ozaki; H Tajiri; K Tanaka-Taya; S Mushiake; A Kimoto; K Yamanishi; S Okada
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

7.  Detection of a gene cluster that is dispensable for human herpesvirus 6 replication and latency.

Authors:  Kazuhiro Kondo; Hideo Nozaki; Kazuya Shimada; Koichi Yamanishi
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  Laboratory and clinical aspects of human herpesvirus 6 infections.

Authors:  Henri Agut; Pascale Bonnafous; Agnès Gautheret-Dejean
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

9.  CD134 is a cellular receptor specific for human herpesvirus-6B entry.

Authors:  Huamin Tang; Satoshi Serada; Akiko Kawabata; Megumi Ota; Emi Hayashi; Tetsuji Naka; Koichi Yamanishi; Yasuko Mori
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-14       Impact factor: 11.205

10.  Identification of the human herpesvirus 6A gQ1 domain essential for its functional conformation.

Authors:  Takahiro Maeki; Mayuko Hayashi; Akiko Kawabata; Huamin Tang; Koichi Yamanishi; Yasuko Mori
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.